DEA Opioid Prescribing “FAQ” Clarifies Potential Physician Investigation Triggers
This article was originally published in The Pink Sheet Daily
Executive Summary
The “Frequently Asked Questions” document suggests DEA will not target physicians based solely on how many opioid scripts they write. The agency suggests doctors keep records of patients’ chronic pain treatment plans when opioids are prescribed. The FAQ could help ease physician concerns about writing opioid scripts.
You may also be interested in...
NME Slowdown Shows Market Pressure On Me-Toos, Not FDA Caution – Lutter
DURHAM, N.C. - The decline in FDA's tally of new molecular entity approvals stems from fewer approvals of non-innovative products in recent years, while approvals of truly innovative products has largely held steady, according to FDA Deputy Commissioner for Policy, Planning and Preparedness Randall Lutter
Amgen Aranesp, Vectibix Setbacks Illustrate Risks Of Real World Trials
Amgen's failed Anemia of Cancer trial of Aranesp and Panitumumab Advanced Colorectal Cancer Evaluation (PACCE) trial of Vectibix may illustrate the potential pitfalls facing sponsors that conduct "real world" trials of their products
Acomplia’s Large European Cash Market Not Affecting Dropout Rate – Sanofi
A substantial portion of European patients purchasing Sanofi-Aventis' Acomplia pay entirely out-of-pocket for the obesity drug